Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
08 mai 2024 11h00 HE
|
Siren Biotechnology, Inc.
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
07 mai 2024 07h05 HE
|
uniQure Inc.
uniQure announces first quarter 2024 results
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
07 mai 2024 06h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
07 mai 2024 03h00 HE
|
Coave Therapeutics
Clinically meaningful benefit in visual functions and good safety profile of HORA-PDE6b is confirmed at 24-month follow-up Phase I/II results will be discussed with US and...
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
03 mai 2024 07h30 HE
|
Ocugen
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
02 mai 2024 17h00 HE
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
02 mai 2024 07h15 HE
|
Ocugen
MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market
01 mai 2024 14h17 HE
|
Spherix Global Insights
EXTON, PA, May 01, 2024 (GLOBE NEWSWIRE) -- In the landscape of healthcare innovation, retinal disorders, including both inherited and degenerative diseases, have become a leading focus area for...
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
01 mai 2024 07h30 HE
|
Atsena Therapeutics
Subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in two patients Provides evidence that AAV.SPR spreads laterally...
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
30 avr. 2024 08h38 HE
|
Fractyl Health, Inc.
Fractyl Health Announces Multiple Presentations at DDW 2024 Conference and the German Diabetes Association (DDG) Annual Meeting